GlucoTrack, Inc. - Common Stock (GCTK)
0.1873
-0.0129 (-6.44%)
NASDAQ · Last Trade: Apr 3rd, 2:34 PM EDT
Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study Data
By Glucotrack, Inc. · Via GlobeNewswire · April 3, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · March 19, 2025
DETROIT, MICHIGAN - March 19, 2025 ( NEWMEDIAWIRE ) - Paul Goode, President & CEO, GlucoTrack (NASDAQ: GCTK), was recently a guest on Benzinga’s All-Access.
Via TheNewswire.com · March 19, 2025
Safety and performance data from direct blood glucose measurement technology to be featured at international diabetes technology conference
By Glucotrack, Inc. · Via GlobeNewswire · March 19, 2025

Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology
By Glucotrack, Inc. · Via GlobeNewswire · February 26, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 25, 2025
By JE Insights, Benzinga
Via TheNewswire.com · February 25, 2025

The study met its primary endpoint with no procedure or device related serious adverse events reported
By Glucotrack, Inc. · Via GlobeNewswire · February 4, 2025

1-for-20 reverse stock split to become effective as of the opening of trading on February 4, 2025
By Glucotrack, Inc. · Via GlobeNewswire · January 30, 2025

Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes
By Glucotrack, Inc. · Via GlobeNewswire · January 29, 2025

ISO Certification highlights commitment to quality for continuous blood glucose monitor
By Glucotrack, Inc. · Via GlobeNewswire · January 21, 2025

New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes
By Glucotrack, Inc. · Via GlobeNewswire · January 15, 2025

Presentation to feature an update on the Company’s novel continuous blood glucose monitor for patients with diabetes
By Glucotrack, Inc. · Via GlobeNewswire · January 7, 2025

VANCOUVER, BC / ACCESSWIRE / July 26, 2023 / The Power Play by The Market Herald has announced the release of new interviews with GlucoTrack and Acceleware discussing their latest news.
Via ACCESSWIRE · July 26, 2023

NEW YORK, NY / ACCESSWIRE / April 17, 2023 / Aegis Capital Corp. acted as Sole Bookrunner on a $10 Million Underwritten Public Offering for GlucoTrack, Inc. (NASDAQ:GCTK).
Via ACCESSWIRE · April 17, 2023

VANCOUVER, BC / ACCESSWIRE / October 27, 2022 / The Power Play by The Market Herald has announced the release of new interviews with NextSource, Good Natured Products, SoLVBL, Geologica and GlucoTrack discussing their latest news.
Via ACCESSWIRE · October 27, 2022

INDUSTRY VETERAN TO LEAD NEW CONTINUOUS GLUCOSE MONITORING R&D PROGRAM
By GlucoTrack, Inc. · Via GlobeNewswire · October 14, 2022

VANCOUVER, BC / ACCESSWIRE / October 12, 2022 / The Power Play by The Market Herald has announced the release of new interviews with SoLVBL, C3 Metals, Charbone Hydrogen, GlucoTrack and Atomic Minerals discussing their latest news.
Via ACCESSWIRE · October 12, 2022

Rutherford, NJ, Oct. 10, 2022 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a non-invasive device and digital health platform for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today it is expanding its product pipeline with the commencement of a new R&D program for a long-term continuous glucose monitor.
By GlucoTrack, Inc. · Via GlobeNewswire · October 10, 2022